Editorial Policy. The Journal of Nuclear Medicine (JNM) publishes material of interest to practitioners and scientists in the fields of nuclear medicine and molecular imaging.Proffered …

The Journal of Nuclear Medicine (JNM)—self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a nonprofit, international scientific and professional …

Jan 1, 2025 · PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177 Lu-PSMA-617: …

The Journal of Nuclear Medicine (JNM)—self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a nonprofit, international scientific and professional …

View or Listen to JNM Podcast; Visit JNM on Facebook; Join JNM on LinkedIn; Follow JNM on Twitter; Subscribe to our RSS feeds

Solving challenging puzzles: Heather Jacene, MD, talks about her career as a clinical innovator in nuclear medicine and leadership roles in the

Dec 1, 2020 · Wolfgang A. Weber and Johannes Czernin. Scientific discoveries published in The Journal of Nuclear Medicine over the past 60 years have shaped the practice of medicine and …

Feb 1, 2023 · IV. COMMON CLINICAL INDICATIONS. Clinical indications for the use of SSTR PET have been previously discussed in the Appropriate Use Criteria (AUC) for SSTR PET, …

Jun 9, 2024 · 177 Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177 Lu-PSMA-I&T Therapy

Oct 1, 2022 · The application of radiopharmaceutical therapy for the treatment of certain diseases is well established, and the field is expanding. New therapeutic radiopharmaceuticals have …